Patients who were prescribed first DOACs between January 1, 2019 to December 31, 2020 Direct oral anticoagulant, dosing, kidney impairment
Conditions
Interventions
Patients who were prescribed first DOACs between January 1, 2019 to December 31, 2020
Treatment
Patients receiving DOAC
Sponsors
Faculty of Medicine Siriraj Hospital Mahidol University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients with eGFR <60 mL/min/1.73 m2 assessed by CKD-EPI equation
Exclusion criteria
Exclusion criteria: Patients who lost follow-up during the study period, patients who do not have a baseline serum creatinine within 3 months, and patients unable to have serum creatinine monitored for 6 months after the previous visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The optimal dose of DOACs that complies with the prescribing information 12 months after first DOAC prescribing The proportion of appropriate DOAC dosing | — |
Secondary
| Measure | Time frame |
|---|---|
| The consistency between the prescribed dose and the prescribing information 12 months after first DOAC prescribing The proportion of consistency between the prescribed dose and the prescribing information | — |
Countries
Thailand
Contacts
Public ContactJunporn Kongwatcharapong
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed